IDEAYA Biosciences Announces Phase 1 Trial Data Presentation for IDE849 in Small-Cell Lung Cancer at 2025 World Conference on Lung Cancer

Reuters

2025/07/23

<a href="https://laohu8.com/S/IDYA">IDEAYA Biosciences</a> Announces Phase 1 Trial Data Presentation for IDE849 in Small-Cell Lung Cancer at 2025 World Conference on Lung Cancer

IDEAYA Biosciences Inc., in collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd., has announced an upcoming oral presentation of clinical efficacy and safety data for IDE849 (SHR-4849), a potential first-in-class DLL3-TOP1 antibody drug conjugate $(ADC)$. The data will be presented at the IASLC 2025 World Conference on Lung Cancer, scheduled for September 6-9, 2025, in Barcelona, Spain. The presentation will cover results from a Phase 1 trial conducted by Hengrui in China, involving over 70 small-cell lung cancer (SCLC) patients. IDEAYA is also preparing a poster presentation on pre-clinical synergy data between TOP1-payload based ADCs and its PARG inhibitor, IDE161, which could enhance the durability of ADC treatments. The U.S. Phase 1 trial of IDE849 in SCLC patients was initiated in the third quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF34459) on July 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553779257"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553779257\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553779257?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-23 01:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553779257","market":"nz","top_or_hot":-1,"title":"IDEAYA Biosciences Announces Phase 1 Trial Data Presentation for IDE849 in Small-Cell Lung Cancer at 2025 World Conference on Lung Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> Announces Phase 1 Trial Data Presentation for IDE849 in Small-Cell Lung Cancer at 2025 World Conference on Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IDEAYA Biosciences Inc., in collaboration with <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals Co., Ltd., has announced an upcoming oral presentation of clinical efficacy and safety data for IDE849 (SHR-4849), a potential first-in-class DLL3-TOP1 antibody drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>. The data will be presented at the IASLC 2025 World Conference on Lung Cancer, scheduled for September 6-9, 2025, in Barcelona, Spain. The presentation will cover results from a Phase 1 trial conducted by Hengrui in China, involving over 70 small-cell lung cancer (SCLC) patients. IDEAYA is also preparing a poster presentation on pre-clinical synergy data between TOP1-payload based ADCs and its PARG inhibitor, IDE161, which could enhance the durability of ADC treatments. The U.S. Phase 1 trial of IDE849 in SCLC patients was initiated in the third quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF34459) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEAYA Biosciences Announces Phase 1 Trial Data Presentation for IDE849 in Small-Cell Lung Cancer at 2025 World Conference on Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEAYA Biosciences Announces Phase 1 Trial Data Presentation for IDE849 in Small-Cell Lung Cancer at 2025 World Conference on Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-23 01:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> Announces Phase 1 Trial Data Presentation for IDE849 in Small-Cell Lung Cancer at 2025 World Conference on Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IDEAYA Biosciences Inc., in collaboration with <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals Co., Ltd., has announced an upcoming oral presentation of clinical efficacy and safety data for IDE849 (SHR-4849), a potential first-in-class DLL3-TOP1 antibody drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>. The data will be presented at the IASLC 2025 World Conference on Lung Cancer, scheduled for September 6-9, 2025, in Barcelona, Spain. The presentation will cover results from a Phase 1 trial conducted by Hengrui in China, involving over 70 small-cell lung cancer (SCLC) patients. IDEAYA is also preparing a poster presentation on pre-clinical synergy data between TOP1-payload based ADCs and its PARG inhibitor, IDE161, which could enhance the durability of ADC treatments. The U.S. Phase 1 trial of IDE849 in SCLC patients was initiated in the third quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF34459) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL6h2lzv:1","article_id":"2553779257","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553779257","pubTimestamp":1753203682,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IDEAYA Biosciences Announces Phase 1 Trial Data Presentation for IDE849 in Small-Cell Lung Cancer at 2025 World Conference on Lung Cancer. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on July 22, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IDYA":"IDEAYA Biosciences"},"translate_title":"IDEAYA Biosciences宣布在2025年世界肺癌大会上展示IDE849治疗小细胞肺癌的1期试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":0.9},"content_text":"IDEAYA Biosciences Announces Phase 1 Trial Data Presentation for IDE849 in Small-Cell Lung Cancer at 2025 World Conference on Lung Cancer\n    \n\n        IDEAYA Biosciences Inc., in collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd., has announced an upcoming oral presentation of clinical efficacy and safety data for IDE849 (SHR-4849), a potential first-in-class DLL3-TOP1 antibody drug conjugate $(ADC)$. The data will be presented at the IASLC 2025 World Conference on Lung Cancer, scheduled for September 6-9, 2025, in Barcelona, Spain. The presentation will cover results from a Phase 1 trial conducted by Hengrui in China, involving over 70 small-cell lung cancer (SCLC) patients. IDEAYA is also preparing a poster presentation on pre-clinical synergy data between TOP1-payload based ADCs and its PARG inhibitor, IDE161, which could enhance the durability of ADC treatments. The U.S. Phase 1 trial of IDE849 in SCLC patients was initiated in the third quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF34459) on July 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}